GlassScriptPhysician profile
David B Doman
NPI 1700889631
$9,544.07
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $1,521 · 2021: $2,016 · 2022: $2,153 · 2023: $1,861 · 2024: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $13.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.13 |
| Education | $13.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,066.61 | 2019-2024 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,521.01 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $914.61 | 2019-2024 | |
| Janssen Biotech, INC. | $747.87 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $600.30 | 2019-2024 | Ocaliva |
| Celgene Corporation | $456.42 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $442.21 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $370.00 | 2021-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $315.66 | 2019-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $261.40 | 2019-2024 | Linzess |
| Genzyme Corporation | $203.46 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $178.94 | 2020-2024 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $177.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $172.33 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $168.55 | 2023-2024 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $129.22 | 2023 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $106.15 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $92.03 | 2019-2020 | |
| Biofire Diagnostics, LLC | $84.96 | 2019 | |
| Encore Medical, LP | $74.34 | 2020 | |
| Redhill Biopharma INC. | $71.10 | 2021 | |
| Ferring Pharmaceuticals INC. | $63.97 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $44.71 | 2022-2024 | Dupixent |
| Pfizer INC. | $41.46 | 2023 | |
| Allergan, INC. | $39.80 | 2019-2020 | |
| Digestive Care, INC. | $37.67 | 2024 | Pertzye |
| Alfasigma USA, INC. | $31.96 | 2020 | |
| Ethicon US, LLC | $29.55 | 2022 | |
| Endo Pharmaceuticals INC. | $27.12 | 2021 | |
| Organon LLC | $22.55 | 2023 | Hadlima, Renflexis |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.81 | 2022 | |
| Romark Laboratories, Lc | $17.74 | 2020 | |
| Daiichi Sankyo INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Doman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.